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Abstract 
A Selective antagonist of prostaglandin E receptor subtype 4 attenuates 
abdominal aortic aneurysm 
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Introduction: 
Abdominal aortic aneurysm (AAA) is a relatively common progressive lethal disease 
among the elderly in most countries (Mani et. al. 2011), but there is currently no proven 
medical therapy. The 30-day mortality after ruptured AAA repair remains high (28%) (Lilja et 
al. 2017). Therefore, the pharmacological strategy to inhibit or slow AAA progression is 
desired. 
Dysregulation of PGE2-mediated inflammatory responses has been suggested to cause 
AAA. Patient-derived tissues show high cyclooxygenase-2 (COX-2) and PGE2 expression 
(Homes et al. 1997), and mouse studies showed that COX-2-PGE2 signaling inhibition or 
genetic-depletion attenuated the progression of AAA (Wang et al. 2008). It is reported that 
EP4 expression was upregulated in human AAA tissues and was correlated with 
degeneration of elastic fibers (Yokoyama et al. 2012). It has been reported that an EP4 
antagonist ONO-AE3-208 attenuated angiotensin II (AngII)-induced AAA in apolipoprotein 
knockout (ApoE-/-) mice (Yokoyama et al. 2012), suggesting that inhibition of EP4 signaling 
has a potential to attenuate AAA progression. 
Therefore, we aimed to examine in mouse AAA models whether EP4 
antagonist-mediated AAA attenuation is a class effect, and investigate whether an EP4 
antagonist inhibits matrixmetalloproteinase (MMP) activation and cytokine release in human 
smooth muscle cells isolated from patients with AAA (hAASMCs). Furthermore we 
demonstrated the role of EP4 signaling in vascular inflammation and AAA development 
using vascular smooth muscle cell (VSMC)-specific EP4 knockout. 
 
Materials and Methods: 
Male ApoE-/- mice, EP4fl/+;ApoE-/- mice and EP4fl/+;SM22Cre;ApoE-/- mice (5-6 months 
of age) were infused with AngII (1 µg/kg/min) for four weeks via an osmotic mini pump (Alzet, 
model 2004, Cupertino, CA, USA) as described previously (Daugherty et al. 2004). AAA was 
induced in male wild type (C57BL/6) mice, EP4fl/+ mice, EP4+/+;SM22Cre mice and 
EP4fl/+;SM22Cre mice (5-6 months of age) by periaortic application of 0.5 M CaCl2 
between the renal arteries and bifurcation of the iliac arteries as described previously 
(Longo et al. 2002). 
CJ-42794 (0.2 mg/kg/day) was orally administrated for four weeks. At the end of the 
experimental period, aorta samples were perfusion fixed with 10% buffered-formalin for 
immunohistochemistry and histological analysis. Elastica van Geison staining was used to 
examine the extent of elastin fiber degradation and gelatin zymography was performed for 
MMP assay as described previously (Yokoyama et al. 2012). Interleukin-6 (IL-6) contents 
were measured using ELISA (R&D Systems) and blood pressure of mice was measured by 
the tail-cuff method using a BP-98A-L (Softron, Tokyo, Japan). 
 
Results: 
Oral administration of CJ-42794 significantly decreased AAA formation in ApoE-/- mice 
infused with AngII, in which elastic fiber degradation and activations of MMP2 and MMP9 
were attenuated. IL-6 proteins were highly expressed in medial layer of AngII-induced 
mouse AAA tissues, whereas CJ-42794 treatment significantly decreased IL-6 protein 
expression. AAA formation induced by periaortic CaCl2 application in wild type mice was 
also reduced by oral administration of CJ-42794 for four weeks. When oral administration of 
CJ-42794 started two weeks after periaortic CaCl2 application and continued for additional 
four weeks, aortic diameter and elastic fiber degradation grade were significantly smaller in 
CJ-42794-treated mice than in untreated mice. In hAASMCs, stimulation of CJ-42794 
inhibited PGE2-induced IL-6 secretion in a dose dependent manner and decreased 
PGE2-induced MMP-2 activity. Furthermore, VSMC specific EP4 knockout protected mice 
from AAA induced by (a) AngII infusion in EP4fl/+;SM22Cre;ApoE-/- (hyperchloesterolemic 
mice) (72.7% reduction compared to their control EP4fl/+;ApoE-/-, p˂0.05) and (b) periaortic 
CaCl2 application in EP4fl/+;SM22Cre (nonhypercholesterolemic mice) (70.0% reduction 
compared to their control EP4+/+;SM22Cre, p˂0.05) mice. Deletion of EP4 in VSMCs 
suppressed elastic fiber degradation in both hyperchloesterolemic and 
nonhypercholesterolemic mouse AAA models. 
 
Discussion: 
AAA is a complex multifactorial progressive disease with the features of inflammation, 
MMP activation, oxidative stress, elastin degradation and smooth muscle cell atrophy. 
Hence development of a direct therapeutic target has proven challenging. 
 In the present study, we demonstrated that a selective EP4 antagonist CJ-42794 
decreased AAA formation in both AngII- and CaCl2-induced AAA models. In addition to the 
inhibitory effect of CJ-42794 on AAA formation, we investigated the effect of CJ-42794 on 
the progression phase. Furthermore, the utilization of hAASMCs and VSMC knockout of 
EP4 in mice demonstrated the potential beneficial effects on AAA. These data suggest that 
both pharmacological and genetic inhibition of EP4 attenuated AAA progression in mouse 
models and human VSMCs. 
 Inhibition of PGE2 production by NSAID or COX inhibitors attenuated AAA in mouse 
models (Wang et al. 2008). However, clinical studies have shown that COX-2 inhibition 
induces multiple cardiovascular adverse events (Ray et al. 2002). In this context, selective 
inhibition of downstream of PGE2 was thought to avoid severe adverse effects. Our data 
demonstrated that EP4 antagonist-mediated AAA attenuation is potentially a class effect, 
instead of a drug-specific effect. The selective inhibition of EP4 has potential to attenuate 
AAA progression. 
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